These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 35089113)

  • 61. Use of tocilizumab in kidney transplant recipients with COVID-19.
    Pérez-Sáez MJ; Blasco M; Redondo-Pachón D; Ventura-Aguiar P; Bada-Bosch T; Pérez-Flores I; Melilli E; Sánchez-Cámara LA; López-Oliva MO; Canal C; Shabaka A; Garra-Moncau N; Martín-Moreno PL; López V; Hernández-Gallego R; Siverio O; Galeano C; Espí-Reig J; Cabezas CJ; Rodrigo MT; Llinàs-Mallol L; Fernández-Reyes MJ; Cruzado-Vega L; Pérez-Tamajón L; Santana-Estupiñán R; Ruiz-Fuentes MC; Tabernero G; Zárraga S; Ruiz JC; Gutiérrez-Dalmau A; Mazuecos A; Sánchez-Álvarez E; Crespo M; Pascual J;
    Am J Transplant; 2020 Nov; 20(11):3182-3190. PubMed ID: 32654422
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Single versus multiple doses of Tocilizumab in critically ill patients with coronavirus disease 2019 (COVID-19): A two-center, retrospective cohort study.
    Al Sulaiman K; Aljuhani O; Bin Salah K; Korayem GB; Eljaaly K; Al Essa M; Kharbosh A; Al Harbi F; Abuzaid M; Al Bilal S; Almagthali A; Alsohemi S; Alshabasy A; Noureldeen H; Aboudeif M; Alshehri A; Vishwakarma R
    J Crit Care; 2021 Dec; 66():44-51. PubMed ID: 34438133
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care.
    Taramasso L; Magnasco L; Portunato F; Briano F; Vena A; Giacobbe DR; Dentone C; Robba C; Ball L; Loconte M; Patroniti N; Frisoni P; D'Angelo R; Dettori S; Mikulska M; Pelosi P; Bassetti M
    Eur J Intern Med; 2021 Dec; 94():39-44. PubMed ID: 34511338
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
    Corominas H; Castellví I; Pomar V; Antonijoan R; Mur I; Matas L; Gich I; de Benito N; Laiz A; Castillo D; Villamarin L; Filella D; Millán AM; Quijada MÁ; Puig M; Casademont J; Domingo P
    Clin Immunol; 2021 Feb; 223():108631. PubMed ID: 33189888
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review.
    Kulanthaivel S; Kaliberdenko VB; Balasundaram K; Shterenshis MV; Scarpellini E; Abenavoli L
    Rev Recent Clin Trials; 2021; 16(2):138-145. PubMed ID: 32940187
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hypochloremia: A Potential Indicator of Poor Outcomes in COVID-19.
    Barkay O; Karakeçili F
    Medicina (Kaunas); 2024 Aug; 60(9):. PubMed ID: 39336455
    [No Abstract]   [Full Text] [Related]  

  • 67. Hemophagocytic lymphohistiocytosis in a patient with COVID-19 treated with tocilizumab: a case report.
    Tholin B; Hauge MT; Aukrust P; Fehrle L; Tvedt TH
    J Med Case Rep; 2020 Oct; 14(1):187. PubMed ID: 33054818
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
    Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
    Wu J; Shen J; Han Y; Qiao Q; Dai W; He B; Pang R; Zhao J; Luo T; Guo Y; Yang Y; Wu Q; Jiang W; Zhang J; Zhang M; Li N; Li W; Xia X
    Front Immunol; 2021; 12():598799. PubMed ID: 33746945
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration.
    Conrozier T; Lohse A; Balblanc JC; Dussert P; Royer PY; Bossert M; Bozgan AM; Gendrin V; Charpentier A; Toko L; Badie J; Mezher C; Roux MF; Kadiane-Oussou NJ; Contreras R; Kessler J; Mazurier I; Klopfenstein T; Zayet S
    Clin Exp Rheumatol; 2020; 38(4):742-747. PubMed ID: 32573419
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study.
    Tomasiewicz K; Piekarska A; Stempkowska-Rejek J; Serafińska S; Gawkowska A; Parczewski M; Niścigorska-Olsen J; Łapiński TW; Zarębska-Michaluk D; Kowalska JD; Horban A; Flisiak R
    Expert Rev Anti Infect Ther; 2021 Jan; 19(1):93-100. PubMed ID: 32693650
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tocilizumab shortens time on mechanical ventilation and length of hospital stay in patients with severe COVID-19: a retrospective cohort study.
    Eimer J; Vesterbacka J; Svensson AK; Stojanovic B; Wagrell C; Sönnerborg A; Nowak P
    J Intern Med; 2021 Mar; 289(3):434-436. PubMed ID: 32744399
    [No Abstract]   [Full Text] [Related]  

  • 73. Clinical characteristics and outcomes of critically ill COVID-19 patients in Tokyo: a single-center observational study from the first wave.
    Banno A; Hifumi T; Okamoto H; Masaki M; Seki K; Isokawa S; Otani N; Hayashi K; Ishimatsu S
    BMC Infect Dis; 2021 Feb; 21(1):163. PubMed ID: 33563218
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Tocilizumab in the Management of COVID-19: A Preliminary Report.
    Li M; Yoo EJ; Baram M; McArthur M; Skeehan C; Awsare B; George G; Summer R; Zurlo J; Jallo J; Roman J
    Am J Med Sci; 2021 Feb; 361(2):208-215. PubMed ID: 33358502
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The safety and effectiveness of tocilizumab in older adult critically ill patients with COVID-19: a multicenter, cohort study.
    Korayem GB; Aljuhani O; Altebainawi AF; Shaya AIA; Alnajjar LI; Alissa A; Aldhaeefi M; Kensara R; Al Muqati H; Alhuwahmel A; Alhuthaili O; Vishwakarma R; Aldardeer N; Eljaaly K; Alharbi A; Harbi SA; Katheri AA; Bekairy AMA; Aljedai A; Al Sulaiman K
    Int J Infect Dis; 2022 Sep; 122():252-259. PubMed ID: 35605948
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The Effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19.
    Amin S; Rahim F; Bahadur S; Noor M; Mahmood A; Gul H
    J Coll Physicians Surg Pak; 2021 Jan; 31(1):S7-S10. PubMed ID: 33650415
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study.
    Şener MU; Çiçek T; Öztürk A
    Sao Paulo Med J; 2022; 140(5):627-635. PubMed ID: 35858016
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tocilizumab treatment in severe COVID-19: a multicenter retrospective study with matched controls.
    Mert A; Vahaboğlu H; Arslan F; Batirel A; Saraçoğlu KT; Bastug A; Çağatay A; Irmak İ; Dizman GT; Ertenli İ; Altunal LN; Sengel BE; Bayram M; Omma A; Amikishiyev S; Aypak A; Bes C; Bolukçu S; Içten S; Topeli A; Bektaş M; Arslan BY; Öztürk S; Çomoğlu Ş; Aydin S; Küçükşahin O; Içaçan OC; Ince B; Aghamuradov S; Mutlu MY; Şimşek F; Emre S; Ustun C; Ergen P; Aydin Ö; Koç MM; Sevindik ÖG; Odabaşı Z; Korten V; Bodur H; Güner R; Ünal S; Kocak M; Gül A
    Rheumatol Int; 2022 Mar; 42(3):457-467. PubMed ID: 34515808
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.